Everything you need to cover OncoFirm™ Diagnostics accurately.
Approved company descriptions, a fact sheet, leadership bios, a plain-language explanation of the technology, logo and brand files, and our announcements to date. OncoFirm is a development-stage company: nothing described here has been cleared or approved by the FDA or any other regulator, and we'd rather coverage said so plainly.
Company news and press releases
Every announcement OncoFirm has issued, newest first. The full text of each lives in the newsroom on oncofirm.com.
-
Aug 3, 2026
Press releaseOncoFirm™ Diagnostics Strengthens Intellectual Property Portfolio with Six Patent Applications and Three Trademark Filings
Filings cover fluorescence-enhanced lateral flow diagnostics, multi-biomarker cancer detection, AI-assisted interpretation, handheld digital reader systems, oncology software, and proprietary assay design. Applications remain subject to examination.
-
May 20, 2025
FeatureOncoFirm Diagnostics: Rapid Cancer Screening for Global Health Impact
Why point-of-care cancer screening matters in low- and middle-income countries, and how a lateral flow format designed to run without a laboratory or refrigeration could widen access for ministries of health, NGOs, and community programs.
-
Apr 7, 2025
Press releaseOncoFirm Diagnostics Corp. Announces Launch and Opens First Funding Round Up to $10 Million
The company's launch announcement: an antigen-targeting lateral flow platform for point-of-care cancer detection, an initial product pipeline, and the opening of a first funding round for qualified investors.
-
Apr 1, 2025
Company postRevolutionizing Early Cancer Detection
An introduction to the next-generation lateral flow assay approach: nanoparticle engineering, signal-amplification chemistry, and multiplex detection.
Press coverage
Independent reporting on OncoFirm, listed as it is published.
Coverage will appear here as it is published.
OncoFirm is an early-stage company and has not yet been the subject of independent coverage. If you are working on a story about point-of-care diagnostics, earlier cancer detection, or what fluorescence and AI add to rapid tests, we're glad to provide background, a technical briefing, or an interview with the founder.
Story angles we can speak to
- Cancer biomarker testing outside the central lab. What it takes to move a test from a hospital laboratory to a clinic, a pharmacy, or a field program.
- What fluorescence adds to a lateral flow test. Why a digitally read fluorescent signal differs from the visible line on a familiar rapid test.
- AI-assisted reading of rapid tests. Where software can help with signal interpretation, quality control, and decision support - and where it can't yet.
- Veterinary oncology at the point of care. Affordable cancer screening for companion animals as a parallel application.
- Building a diagnostics company. Lessons from the founder's prior experience scaling a global rapid-test and medical device business.
Follow OncoFirm
Approved company descriptions
Use any of these as written. If you shorten them, please keep the development-stage language intact.
OncoFirm™ Diagnostics Corporation is a Port Washington, New York - based biotechnology company developing rapid, antigen-based diagnostic technologies for the earlier detection of cancer.
OncoFirm™ Diagnostics Corporation is a development-stage biotechnology company building rapid diagnostic technologies for the early detection of cancer. Its platform combines fluorescent lateral flow immunoassays, digital diagnostic readers, and AI-assisted interpretation, with the goal of making cancer biomarker testing faster, more objective, and deployable at the point of care. Headquartered in Port Washington, New York, OncoFirm is developing applications for human healthcare and veterinary oncology. Its products are in development and have not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. Learn more at oncofirm.com.
OncoFirm™ Diagnostics Corporation is a development-stage biotechnology company focused on rapid diagnostic technologies for the early detection of cancer. The company is building a portfolio of proprietary in vitro diagnostic (IVD) platforms that bring together fluorescence-enhanced lateral flow immunoassays, digital diagnostic readers, biomarker discovery, and AI-assisted interpretation, designed to improve the accessibility, speed, and objectivity of cancer biomarker testing across healthcare settings - from hospitals and physician offices to point-of-care and resource-limited environments. OncoFirm's mission is to transform cancer detection through innovative biomarker discovery and next-generation IVD technologies that enable earlier, faster, and more accurate diagnosis; its vision is a future in which highly sensitive biomarker-based diagnostics become the standard of care for cancer screening and disease monitoring. The company is pursuing applications in both human healthcare and veterinary oncology, and in August 2026 announced the filing of six patent applications and three trademark applications covering its platform. OncoFirm is headquartered in Port Washington, New York. Its products and technologies are in development and have not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority. Learn more at oncofirm.com.
Advancing Earlier Cancer Detection. Accelerating Better Outcomes.
Logo lockup line: Detect earlier. Treat smarter. Save lives.
OncoFirm at a glance
- Legal name
- OncoFirm™ Diagnostics Corporation
- Headquarters
- Port Washington, New York 11050, USA
- Founded
- 2025
- Founder & CEO
- Jonathan Adam Barash
- Ownership
- Privately held
- Stage
- Development-stage; products investigational, not cleared or approved by the FDA or any other regulator
- What we're building
- A connected cancer-diagnostic platform: fluorescent lateral flow immunoassays, digital fluorescence readers, and AI-assisted signal interpretation for point-of-care use
- Applications
- Human healthcare (physicians, hospitals, point of care) and veterinary oncology (companion animals)
- Intellectual property
- Six patent applications and three trademark applications filed, announced August 3, 2026 (subject to examination)
- Development roadmap
- Five phases: biomarker & assay research → prototype & reader integration → analytical validation → clinical feasibility → regulatory & scale-up. No dates announced.
- Funding pathways
- Grants, strategic investment, sponsored research, licensing, and co-development
- Team
- 9 - pending; Scientific and Corporate Advisory Boards being assembled
- Website
- oncofirm.com - investor.oncofirm.com
- Phone
- +1 516-900-2606
- Social
- LinkedIn: oncofirm-diagnostics · X and Instagram: @OncoFirm · Facebook: /oncofirm
- Trademark
- OncoFirm™ is a trademark of OncoFirm Diagnostics Corporation
Founder and advisors
Attach 1200 × 1500 px JPG,
plus a square crop
Jonathan Adam Barash
Founder & Chief Executive Officer
Jonathan Adam Barash founded OncoFirm™ Diagnostics and leads company strategy, product development, commercialization, and partnerships. He brings 25 years of global experience as an entrepreneur and executive in rapid diagnostics and medical devices.
He previously founded and scaled a $14 million global medical device company with distribution across 65 countries, designed and trademarked six internationally recognized brands, secured USAMMCE grants for hepatitis and HCV rapid tests, and directed the construction and FDA compliance of a 30,000-square-foot ISO 13485 manufacturing facility. That company was recognized among the top five global companies in the 2008 point-of-care diagnostics industry report.
Jonathan Adam Barash is the Founder and Chief Executive Officer of OncoFirm™ Diagnostics Corporation, a development-stage company building rapid, point-of-care technologies for the earlier detection of cancer. He brings 25 years of experience as an entrepreneur and executive in rapid diagnostics and medical devices, including founding and scaling a global medical device company with distribution in 65 countries.
Advisory boards
OncoFirm is assembling Scientific and Corporate Advisory Boards spanning oncology, molecular diagnostics, regulatory affairs, clinical medicine, and biotechnology commercialization. Members are announced individually once appointments are finalized; see About Us for the current roster.
How the OncoFirm platform is designed to work
A rapid test in a familiar format, read by an instrument instead of the eye. Everything below describes intended functionality of a platform in development.
-
A sample is applied
The sample enters the well of a single-use cassette and moves along the test strip by capillary action - the same principle as familiar rapid tests.
-
Antibodies capture the target
Immune complexes form as the sample crosses the strip and are captured at the test line; fluorescent labels bind where the target biomarker is present. A control line confirms the test ran.
-
A reader measures the signal
Instead of a visible color change, a digital reader excites the fluorescent labels with controlled light and measures the emitted intensity with high-sensitivity sensors, producing a standardized digital result.
-
Software interprets and connects
Embedded software handles normalization, calibration, and quality control, with connectivity to laboratory and health-record systems. AI-assisted interpretation and decision support are planned capabilities.
Why fluorescence, in the company's words
Fluorescence-based platforms may provide objective digital measurement, quantitative or semi-quantitative analysis, reduced observer variability, and multiplex biomarker capability. OncoFirm's own caveat: the extent of these advantages depends on assay design, instrumentation, and clinical validation. The platform is designed to complement, not replace, established laboratory diagnostics.
Biomarkers and pipeline concepts
The platform targets tumor-associated antigens and protein biomarkers; the April 2025 launch announcement cited Thomsen-Friedenreich (TF) and Gal-GalNAc antigens and named pipeline concepts for colorectal and pancreatic (OncoFirm™-R), breast and ovarian (OncoScreen-B), lung (OncoFirm™-L), prostate (OncoFirm™-PSA), liver (OncoFirm™-AFP), and gastrointestinal cancers (OncoFirm™-CEA), plus a multiplex test (OncoFirm™ MultiDx). All are concept-stage. No performance data have been published.
Quotable, as published
Attribute to Jonathan Adam Barash, Founder & CEO, OncoFirm™ Diagnostics Corporation. Need a quote on a specific angle? Ask - we usually turn one around the same day.
"Our mission is to democratize early cancer detection. By leveraging our antigen-driven technology, we're equipping healthcare providers with fast, affordable, and accessible tools to detect cancer earlier-even in settings without traditional laboratory infrastructure."
"Our intellectual property strategy is one of the cornerstones of our business. Filing six patent applications and three trademark applications demonstrates our commitment to building a world-class diagnostics company focused on innovation, scientific excellence, and technologies that have the potential to improve cancer detection worldwide. While this is an important milestone, we believe it is only the beginning."
"Lateral flow tests have already proven they can bring testing to the point of care. Our work is about giving that format the objectivity of a laboratory measurement - a fluorescent signal, a digital reader, and software that helps clinicians interpret what they're seeing."
Logo files and usage
The OncoFirm™ logo is the globe mark, wordmark, "Diagnostics" rule, and tagline as one lockup. Use the files below rather than screenshots or recreations.
Primary logo · on white
Primary logo · on Cloud #EDF2F7
Clear space and minimum size
- Keep clear space around the logo equal to the height of the "O" in OncoFirm on all sides.
- Minimum width: 140 px on screen; 35 mm in print. Below that, use the mark and wordmark without the tagline.
- Always include the ™ symbol; it is part of the artwork.
- Place the logo on white or a light neutral. On dark or photographic backgrounds use the reversed (white) version on a solid panel.
Do
- Use the supplied files at their native proportions
- Keep OncoFirm Blue or the reversed white version
- Pair the logo with the tagline as supplied
Don't
- Stretch, rotate, outline, or add shadows or gradients
- Recolor the mark or set the wordmark in another typeface
- Remove the ™ or separate the tagline from the lockup
Color palette
Values below are the digital brand palette in use on oncofirm.com. Print equivalents: [add CMYK / Pantone from the print vendor]
Typography
Writing the name
| Use | Avoid | Note |
|---|---|---|
| OncoFirm™ Diagnostics Corporation | Oncofirm Diagnostics Corp., ONCOFIRM | Full legal name on first reference in formal contexts. Capital O, capital F, no space. |
| OncoFirm™ Diagnostics | Onco Firm, Onco-Firm, OncoFirm Dx | Standard first reference. Include ™ on the first or most prominent use on a page. |
| OncoFirm | the OncoFirm, OF | Subsequent references. Pronounced ON-co-firm. |
| OncoFirm™ Fluorescent Lateral Flow Platform | OncoFirm test kit, OncoFirm cancer test | The platform, not a product. No product is available for sale. |
Photography and renderings
High-resolution files for editorial use. Every product image is a concept rendering and must carry the caption below.
Jonathan Adam Barash
1200 × 1500 JPG
Founder & CEO portrait
Credit: Courtesy of OncoFirm™ Diagnostics Corporation
Cassette + digital reader
3000 px wide, PNG
Platform concept rendering
Mandatory caption applies. Credit: OncoFirm™ Diagnostics Corporation
Reader screen, result view
3000 px wide, PNG
Reader interface concept
Mandatory caption applies. Results shown are illustrative, not clinical data.
Lab / assay development
3000 px wide, JPG
Laboratory photography
Credit: Courtesy of OncoFirm™ Diagnostics Corporation
Logo lockups, light and reversed
SVG + PNG
Logo lockups
Same files as the brand section, packaged for layout.
Founder explainer, 2"“3 min
1080p MP4 + captions
Founder explainer video
B-roll of the platform concept and a short interview. Embed or download.
Mandatory caption for all product images and renderings
Concept rendering. The OncoFirm™ device and results shown are illustrative of intended functionality; the product is in development and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority.
Usage rights. Images in this kit may be reproduced by news organizations for editorial coverage of OncoFirm without further permission, with credit as noted. They may not be altered beyond cropping, used to imply endorsement, or used in advertising. For any other use, contact us.
Questions we're asked most
Can I buy an OncoFirm test today? Is anything approved?
No. OncoFirm's products and technologies are in development. Nothing has been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority, and no product is available for sale. Please describe the company as "development-stage" and its platform as "in development" or "investigational."
In one sentence, what is OncoFirm building?
A rapid cancer-diagnostic platform that pairs fluorescent lateral flow tests with a digital reader and AI-assisted software, intended to make cancer biomarker testing faster, more objective, and usable at the point of care.
How is this different from a standard rapid test?
A standard lateral flow test shows a colored line that a person reads by eye. OncoFirm's design uses fluorescent labels that are measured by an instrument under controlled light, which the company expects may allow objective digital measurement, quantitative or semi-quantitative results, and several biomarkers on one strip. OncoFirm's own caveat is that the extent of those advantages depends on assay design, instrumentation, and clinical validation.
Which cancers, and how accurate is it?
The platform targets tumor-associated antigens and protein biomarkers. Pipeline concepts named at launch span colorectal, pancreatic, breast, ovarian, lung, prostate, liver, and gastrointestinal cancers, plus a multiplex test. No clinical performance data have been published, so please don't cite sensitivity, specificity, or accuracy figures for OncoFirm's platform.
Where is OncoFirm in development?
The company describes a five-phase roadmap: biomarker and assay research, prototype and reader integration, analytical validation, clinical feasibility, and regulatory review and scale-up. It has not announced dates for those phases. In August 2026 it announced six patent applications and three trademark applications covering the platform.
Is OncoFirm public? Who funds it?
OncoFirm™ Diagnostics Corporation is privately held and headquartered in Port Washington, New York. It pursues grants, strategic investment, sponsored research, licensing, and co-development. Investor inquiries go through investor.oncofirm.com; nothing in this kit is an offer to sell or a solicitation to buy securities.
Does the platform have uses beyond human medicine?
Yes. OncoFirm is also developing point-of-care cancer screening concepts for veterinary oncology, aimed at affordable testing for companion animals.
Are the device images real?
They are concept renderings that illustrate intended functionality. Please run them with the mandatory caption in the Images section.
Can I interview the founder or visit the company?
Interviews with Jonathan Adam Barash, Founder and CEO, are available by phone, video, or in person in the New York area. Contact details are at the top and bottom of this page.
Describing OncoFirm accurately
A short style guide for reporters and editors. It exists to keep coverage accurate for readers, patients, and clinicians.
| Topic | Say | Don't say |
|---|---|---|
| Company stage | development-stage biotechnology company; platform in development; investigational technology | launched product; available now; FDA-approved, FDA-cleared, clinically validated, clinically proven |
| The technology | a fluorescent lateral flow platform with digital readers and AI-assisted interpretation, designed for point-of-care cancer biomarker testing | a blood test that detects cancer; a cancer-screening kit; a replacement for laboratory testing |
| Performance | OncoFirm has not published clinical performance data | any sensitivity, specificity, accuracy, or "results in X minutes" figure presented as a demonstrated result |
| Timelines | the company has outlined a five-phase roadmap without announced dates | expected launch dates or approval dates |
| Quotes | quotes from this kit or provided in writing by the company | paraphrases presented as direct quotes |
| Images | concept renderings with the mandatory caption | renderings captioned as photographs of a finished product |
Fact-checking
We will check technical and regulatory statements before publication on request, and aim to respond within one business day.
Embargoes
We honor embargoes agreed in writing and will share materials ahead of announcements with reporters who request them.
Corrections
If a published piece contains an error about OncoFirm, we'll contact the outlet with the correct information and the source for it.
Reach the right person
Jonathan Adam Barash
Founder & Chief Executive Officer
+1 516-900-2606
[add press email]
Interviews, background briefings, fact-checking, speaking requests, and image permissions.
Investor inquiries
Information for qualified strategic investors, foundations, and federal programs is handled separately through the investor site, subject to its disclaimer.
Research and collaboration
Clinical collaborators, research institutions, and distribution or licensing partners can start with the collaboration inquiry form.
Mailing address: OncoFirm™ Diagnostics Corporation, Port Washington, New York 11050, USA [add street address if you want it published]